GoodGuyBill
17 minutes ago
$5–$10 is absurd. DCVax works, targeting all tumor-based cancers, is highly scalable, and is extensively protected by patents.
Meanwhile, Merck's Keytruda, which accounts for 46% of the company's total revenue, faces patent expiration in 2028. Currently, four Keytruda biosimilars exis